详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department Of Medical Oncology, Cancer Institute/Hospital, PekingUnion Medical College & Chinese Academy Of Medical Sciences,BeijingKey Laboratory Of Clinical Study On Anticancer Molecular TargetedDrugs/China, [2]Beijing Chest Hospital, Capital Medical University/China, [3]Peking Union Medical College Hospital/China, [4]Henan CancerHospital/China, [5]Medical Oncology, Guangzhou Chest Hospital/China, [6]Department Of Cancer, Union Hospital Of Tongji Medical College/China, [7]Fourth Hospital, Hebei Medical University/China, [8]309 Hospital/China, [9]South Hospital/China, [10]301 Hospital/China, [11]Liaoning CancerHospital/China, [12]Sichuan Cancer Hospital/China, [13]Qilu Hospital,Shandong University/China, [14]The First Hospital Of China Medical Universtiy/China, [15]Shandong Cancer Hospital/China, [16]Peking UniversityFirst Hospital/China, [17]The First Affiliated Hospital Of Dalian MedicalUniversity/China

出处：

ISSN：

关键词： EGFR mutation lung adenocarcinoma

语种：

WOS：

中科院(CAS)分区：

出版当年[2013]版：

大类 | 2 区医学

小类 | 2 区呼吸系统 3 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2013]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 5.8 出版当年[2013版] 4.948 出版当年五年平均 4.473 出版前一年[2012版] 5.282 出版后一年[2014版]

第一作者：

第一作者机构： [1]Department Of Medical Oncology, Cancer Institute/Hospital, PekingUnion Medical College & Chinese Academy Of Medical Sciences,BeijingKey Laboratory Of Clinical Study On Anticancer Molecular TargetedDrugs/China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinoma [2]Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation [3]EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. [4]Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer [5]EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. [6]First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE). [7]First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE) [8]18f-fdgpet/ct影像组学特征对肺腺癌患者egfr基因突变的预测价值 [9]First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE) [10]First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study